摘要
对58例原发性肝癌和24例转移性肝癌患者采用载药微球经导管灌注化疗栓塞治疗,采用改良实体肿瘤疗效评价标准对2组患者进行疗效评价,比较2组患者治疗后肝功能变化及术后并发症发生率。原发组和转移组治疗后的1个月疾病缓解率分别为74.14%和50.00%,疾病控制率分别为100.00%和75.00%,差异有统计学意义(P<0.05)。转移组肝脏功能损害高于原发组(P<0.05)。2组患者术后均出现不同程度的并发症,但转移组发生概率高于对照组,部分差异有统计学意义。CalliSpheres载药微球经导管灌注化疗栓塞肝癌安全有效,在疗效方面原发性肝癌比转移性肝癌更为确切,安全性更高。
58 patients with primary hepatic cancer and 24 patients with metastatic hepatic cancer were treated by transcatheter chemoembolization with drug-eluting beads microspheres.The curative effect of the two groups was evaluated by modified response evaluation criteria in solid tumors(mRECIST).The changes of liver function before and after treatment and the occurrence of postoperative complications were compared between the two groups.After a month treatment,the objective response rate(CR+PR)was 74.14%in primary group,50.00%in metastatic group;the disease control rate was 100.00%and 75.00%respectively.The difference was statistically significant(P<0.05).The damage of liver function in the metastatic group was more serious than that in the primary group(P<0.05).Complications were occurred in both groups.The incidence in the metastatic group was significantly higher than that in the control group.Transcatheter chemoembolization with Calli Spheres drug-eluting beads microspheres is safe and effective for hepatic cancer,and primary hepatic cancer is more accurate and safer than that of metastatic hepatic cancer.
作者
宋文
彭赵宏
张德志
李晓舒
张国兵
施万印
熊壮
赵本胜
汪名权
陶龙香
Song Wen;Peng Zhaohong;Zhang Dezhi(Dept of Radiology,The First Afilited Hospital of Anhui Medical University,Hefei 230022)
出处
《安徽医科大学学报》
CAS
北大核心
2020年第8期1307-1311,共5页
Acta Universitatis Medicinalis Anhui
基金
国家自然科学基金(编号:81901726)。
